IMOS vs NVDA

Despite a strong Piotroski F-Score of 7/9 indicating solid operational health, IMOS is severely overvalued with a current price of $40.91 far exceeding its Graham Number ($14.41) and Intrinsic Value ($12.69). While the company shows impressive earnings growth (126.8% YoY), its profitability is precarious with a razor-thin profit margin of 2.07%. Most concerning is the unsustainable dividend payout ratio of 176.43%, suggesting the dividend is funded by capital or debt rather than earnings. The combination of a bearish technical trend (10/100) and extreme valuation multiples makes the current entry point high-risk.

NVDA exhibits strong financial health with a Piotroski F-Score of 7/9, indicating robust operational efficiency and solvency. While the current price of $182.08 is significantly above the Graham Number ($26.71) and the growth-based intrinsic value ($144.55), the stock is fundamentally undervalued relative to its growth, as evidenced by a PEG ratio of 0.72 and a highly attractive Forward P/E of 16.38. The company's elite profitability margins (55.6% profit margin) and minimal debt (0.07 D/E) provide a massive cushion for volatility. Despite bearish insider sentiment and short-term technical weakness, the long-term growth trajectory remains exceptionally strong.